Ixazomib in the Treatment of Relapsed Multiple Myeloma

Medical Council
doi 10.21518/2079-701x-2018-10-84-91
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Remedium, Ltd.

Related search

Phase I/Ii Trial of Bendamustine, Ixazomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib

Blood Cancer Journal
OncologyHematology
2015English

Pcn73 - Budget Impact of Ixazomib in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in Russia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn104 - Economic Analysis of Costs and Resource Consumption of Ixazomib in Patients With Relapsed / Refractory Multiple Myeloma in Austria

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma With Extramedullary Disease

Cancers
Cancer ResearchOncology
2020English

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology
Oncology
2018English

Nuclear Medicine Imaging of Multiple Myeloma, Particularly in the Relapsed Setting

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2016English

Emerging Role of Carfilzomib in Treatment of Relapsed and Refractory Lymphoid Neoplasms and Multiple Myeloma

Core Evidence
MedicineReviewsReferencesPharmacology
2011English

Daratumumab vs. Pomalidomide for the Treatment of Relapsed/Refractory Multiple Myeloma: A Cost‐effectiveness Analysis

American Journal of Hematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy